Actively Recruiting
Double-Blind, Placebo-Controlled Phase 2 Study Evaluating Oral ACP-204 for Adults with Lewy Body Dementia Psychosis
Led by ACADIA Pharmaceuticals Inc. · Updated on 2026-11-04
180
Participants Needed
62
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ACP-204 in adults with Lewy Body Dementia Psychosis LBDP. This study aims to understand how ACP-204 affects psychosis symptoms in participants aged 55 to under 85 years. It compares two doses of ACP-204 against a placebo over a six-week period. Participants are assigned to one of three groups receiving 30 mg of ACP-204 once daily, 60 mg of ACP-204 once daily, or a placebo once daily. The medication is provided as a capsule taken orally. The study lasts six weeks, during which participants take their assigned treatment daily while remaining unaware of their group assignment. Throughout the trial, participants will be monitored regularly to assess changes in their psychosis symptoms using the SAPS-LBDP total score at week 6. Safety and tolerability will also be evaluated. The study includes screening for eligibility, regular visits during treatment, and assessments to track symptom changes and any side effects over the six-week treatment period.
CONDITIONS
Brief Title
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Research Team
K
Kristin Kidd
B
Becky Howell
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here